New aspects of an old drug: Metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser

Diabetologia

Volumn 54, Issue 2, 2011, Pages 219-222

  Cho, Y M ^a,b   Kieffer, T J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Seoul National University   (South Korea)

Author keywords

Dipeptidyl peptidase 4; Glucagon like peptide 1; Incretin; Metformin; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FENOFIBRATE; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INCRETIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; ROSIGLITAZONE; SULFONYLUREA;

DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENETIC POLYMORPHISM; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PPAR ALPHA; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION;

EID: 78951479936     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1986-3     Document Type: Review

References (31)

1. DM Nathan JB Buse MB Davidson, et al. 2009 Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 52 17 30 1:STN:280:DC%2BD1cjotVGitQ%3D%3D 10.1007/s00125-008-1157-y 18941734
2. WC Knowler E Barrett-Connor SE Fowler, et al. 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 393 403 1:CAS:528:DC%2BD38XhtVWqurc%3D 10.1056/NEJMoa012512 11832527
3. CJ Bailey RC Turner 1996 Metformin N Engl J Med 334 574 579 1:CAS:528:DyaK28XhvVCjs74%3D 10.1056/NEJM199602293340906 8569826
4. RE Amori J Lau AG Pittas 2007 Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 194 206 1:CAS:528:DC%2BD2sXnslSjuro%3D 10.1001/jama.298.2.194 17622601
5. OJ Phung JM Scholle M Talwar CI Coleman 2010 Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 303 1410 1418 1:CAS:528: DC%2BC3cXksl2hsLk%3D 10.1001/jama.2010.405 20388897
6. RE Pratley M Nauck T Bailey, et al. 2010 Liraglutide vs sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 1447 1456 1:CAS:528:DC%2BC3cXltFOmsLo%3D 10.1016/S0140-6736(10)60307-8 20417856
7. E Mannucci A Ognibene F Cremasco, et al. 2001 Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects Diabetes Care 24 489 494 1:CAS:528:DC%2BD3MXit1erur0%3D 10.2337/diacare.24.3.489 11289473
8. E Mannucci F Tesi G Bardini, et al. 2004 Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes Diabetes Nutr Metab 17 336 342 1:CAS:528:DC%2BD2MXktlektL8%3D 15887627
9. N Yasuda T Inoue T Nagakura, et al. 2002 Enhanced secretion of glucagon-like peptide 1 by biguanide compounds Biochem Biophys Res Commun 298 779 784 1:CAS:528:DC%2BD38Xot12kt7g%3D 10.1016/S0006-291X(02)02565-2 12419322
10. A Maida BJ Lamont X Cao DJ Drucker 2011 Metformin regulates the incretin receptor axis via a peroxisome proliferator-activated receptor alpha-dependent pathway in mice Diabetologia 10.1007/s00125-010-1937-z
11. L Lauffer A Grieco R Iakoubov PL Brubaker 2009 Metformin activates the AMPK pathway and improves survival of murine and human L-cells but does not directly increase GLP-1 secretion Diabetologia 52 Suppl 1 198 Abstract
12. X Yao L Chen MS McIntyre, et al. 2010 Biguanide antidiabetic agents increase fecal bile acids via inhibition of apical sodium-dependent bile acid transporter Diabetes 59 Suppl 1 611-P Abstract
13. C Thomas A Gioiello L Noriega, et al. 2009 TGR5-mediated bile acid sensing controls glucose homeostasis Cell Metab 10 167 177 1:CAS:528: DC%2BD1MXhsVChtLnM 10.1016/j.cmet.2009.08.001 19723493
14. JM Lenhard DK Croom DT Minnick 2004 Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments Biochem Biophys Res Commun 324 92 97 1:CAS:528:DC%2BD2cXot1WksLo%3D 10.1016/j.bbrc.2004.09.021 15464987
15. JR Lindsay NA Duffy AM McKillop, et al. 2005 Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes Diabet Med 22 654 657 1:CAS:528:DC%2BD2MXkslKluro%3D 10.1111/j.1464-5491.2005.01461.x 15842525
16. SA Hinke K Kuhn-Wache T Hoffmann RA Pederson CH McIntosh HU Demuth 2002 Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1 Biochem Biophys Res Commun 291 1302 1308 1:CAS:528: DC%2BD38XhslWnsLY%3D 10.1006/bbrc.2002.6607 11883961
17. BJ Goldstein MN Feinglos JK Lunceford J Johnson DE Williams-Herman Sitagliptin 036 Study Group 2007 Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 30 1979 1987 1:CAS:528:DC%2BD2sXpsleksr8%3D 10.2337/dc07-0627 17485570
18. B Ahren G Pacini JE Foley A Schweizer 2005 Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year Diabetes Care 28 1936 1940 1:CAS:528:DC%2BD2MXpsVars7Y%3D 10.2337/diacare.28.8.1936 16043735
19. UK Prospective Diabetes Study Group 1995 U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group Diabetes 44 1249 1258 10.2337/diabetes.44. 11.1249
20. SE Kahn SM Haffner MA Heise, et al. 2006 Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427 2443 1:CAS:528:DC%2BD28Xht12ntrzF 10.1056/NEJMoa066224 17145742
21. G Patane S Piro AM Rabuazzo M Anello R Vigneri F Purrello 2000 Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells Diabetes 49 735 740 1:CAS:528:DC%2BD3cXjsF2msrY%3D 10.2337/diabetes.49.5.735 10905481
22. FC Lynn SA Thompson JA Pospisilik, et al. 2003 A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells FASEB J 17 91 93 1:CAS:528:DC%2BD3sXlvFOgug%3D%3D 12475913
23. EH Koh MS Kim JY Park, et al. 2003 Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats: comparison with PPAR-γ activation Diabetes 52 2331 2337 1:CAS:528: DC%2BD3sXntFequr8%3D 10.2337/diabetes.52.9.2331 12941773
24. M Pruski R Krysiak B Okopien 2009 Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia Diabetes Care 32 1421 1424 1:CAS:528:DC%2BD1MXhtV2gsL7E 10.2337/dc08-2335 19435959
25. M Nieuwdorp ES Stroes JJ Kastelein 2007 Normalization of metabolic syndrome using fenofibrate, metformin or their combination Diabetes Obes Metab 9 869 878 1:CAS:528:DC%2BD2sXhtlOlsLjN 10.1111/j.1463-1326.2006.00668.x 17924869
26. B Ahren JE Foley E Ferrannini, et al. 2010 Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy Diabetes Care 33 730 732 1:CAS:528:DC%2BC3cXlsleqt78%3D 10.2337/dc09-1867 20067974
27. EM Migoya R Bergeron JL Miller, et al. 2010 Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1 Clin Pharmacol Ther 10.1038/clpt.2010.184 21048706
28. V Lyssenko R Lupi P Marchetti, et al. 2007 Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes J Clin Invest 117 2155 2163 1:CAS:528:DC%2BD2sXoslOnsrk%3D 10.1172/JCI30706 17671651
29. L Shu AV Matveyenko J Kerr-Conte JH Cho CH McIntosh K Maedler 2009 Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function Hum Mol Genet 18 2388 2399 1:CAS:528:DC%2BD1MXnt1ehtL0%3D 10.1093/hmg/ddp178 19386626
30. DT Villareal H Robertson GI Bell, et al. 2010 TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action Diabetes 59 479 485 1:CAS:528:DC%2BC3cXhvVyru7Y%3D 10.2337/db09-1169 19934000
31. SA Schäfer K Müssig H Staiger, et al. 2009 A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion Diabetologia 52 1075 1082 10.1007/s00125-009-1344-5 19330314